Trial reportDrug design, development and therapy2024
Comparison of Remimazolam and Propofol in Recovery of Elderly Outpatients Undergoing Gastrointestinal Endoscopy: A Randomized, Non-Inferiority Trial.
Trial report in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Propofol Versus Remimazolam in Gastrointestinal Endoscopy: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials.Digestive diseases and sciences · 2026Pooled it
- Seizure adequacy and safety of remimazolam in electroconvulsive therapy for patients with psychiatric disorders: a double-blind randomized crossover trial.BMC psychiatry · 2026Trial
- Efficacy of enhanced preoxygenation protocols in mitigating hypoxemia during propofol sedation for gastrointestinal endoscopic procedures: a prospective, randomized, controlled study.Medical gas research · 2026Trial
- Effects of Remimazolam Dose and Bolus Injection Rate on Hiccups During Painless Colonoscopy: A Double-Blind Randomized Clinical Trial.Drug design, development and therapy · 2026Trial
- Efficacy of Different Doses of Remimazolam Tosilate Combined with Esketamine in Painless Abortion Patients: A Prospective, Double-Blind, Randomized Controlled Trial.Drug design, development and therapy · 2025Trial
- Efficacy and safety of remimazolam versus propofol in elderly patients undergoing gastrointestinal endoscopy: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2026Article
- Age‑stratified median effective dose (ED₅₀) of remimazolam besylate for successful gastroscope insertion without body movement in geriatric patients.BMC anesthesiology · 2026Article
- Correlation between frailty status and prolonged length of stay in the post-anesthesia care unit and development of a predictive model in elderly patients undergoing painless gastrointestinal endoscopy.Frontiers in medicine · 2026Article
- Assessment of sleep phase, quality, and quantity: the development and validation of the 3-dimensional sleep scale (3DSS).Sleep and biological rhythms · 2026Article
- Comparison of the safety and efficacy of remimazolamFrontiers in pharmacology · 2026Article
- Precision Sedation for Gastrointestinal Endoscopy in Older Adults: Brain Vulnerability and Recovery.Drug design, development and therapy · 2026Review
- What Is the Most Effective Strategy for Acute Postoperative Pain in Total Knee Arthroplasty-Retrospective Observational Study.Journal of clinical medicine · 2025Article
- Safety and efficacy of cipepofol for painless digestive endoscopy in older patients: a randomized, double-blind, non-inferiority trial.BMC geriatrics · 2025Article
- Remimazolam in anesthesia and sedation: A narrative review.Journal of anesthesia and translational medicine · 2025Review
- Advances in the Clinical Application of MAC: A Review of Drug Selection, Combination Therapy, and Administration Methods.Drug design, development and therapy · 2025Review
- Determining the Median Effective Dose of Remimazolam for Anesthesia Induction in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: An Age-Stratified Study.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We designed this trial to compare the recovery time of remimazolam and propofol in elderly patients undergoing painless gastrointestinal endoscopy. Patients and Methods: In this randomized, non-Inferiority trial, 360 patients aged 65 years or older, scheduled for elective outpatient gastrointestinal endoscopy, were randomly assigned to the remimazolam combined with fentanyl (RF) group or the propofol combined with fentanyl (PF) group. The primary outcome was the post-anesthesia care unit (PACU) stay time, defined as the time from the end of the examination to scoring 9 points using the Modified Post-Anesthetic Discharge Scoring System (MPADSS) criteria. Secondary outcomes included sedation-related adverse events, recall, injection pain, as well as postoperative Quality of Recovery-15 (QoR-15) scores and Pittsburgh Sleep Quality Index (PSQI) scores at 1 day, 1 week, and 1 month postoperatively. Results: A total of 351 patients completed the study, with 174 receiving remimazolam and 177 receiving propofol. The PACU stay time in RF group was non-inferior to that in PF group [14 (11, 18) vs 13 (10, 17), mean difference 1 (95% confidence interval 0, 2), Conclusion: This non-inferiority study revealed that in elderly outpatients undergoing gastrointestinal endoscopy, remimazolam achieved recovery times comparable to propofol, with fewer associated complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.